Status:
COMPLETED
Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer
Lead Sponsor:
Pfizer
Conditions:
Kidney Neoplasms
Carcinoma, Renal Cell
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
To determine the activity and response rate of AG-013736 in patients with advanced and refractory renal cell cancer, (patients who also failed on sorafenib-based therapy).
Eligibility Criteria
Inclusion
- RCC with metastases and nephrectomy
- failure of prior sorafenib-based therapy
- at least 1 target lesion that has not been irradiated
- adequate bone marrow, hepatic and renal function, \> or equal to 18 years of age.
Exclusion
- Gastrointestinal abnormalities
- current use or inability to avoid chronic antacid therapy
- current use or anticipated inability to avoid potent CYP3A4 inhibitors or CYP1A2 inducers
- active seizure disorder or evidence of brain metastases.
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT00282048
Start Date
March 1 2006
End Date
June 1 2009
Last Update
July 31 2012
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Chicago, Illinois, United States, 60637
2
Pfizer Investigational Site
The Bronx, New York, United States, 10466
3
Pfizer Investigational Site
Cleveland, Ohio, United States, 44195
4
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States, 19111-2497